What is JBIO's price / book?

JBIO (JBIO) reported price / book of 2.3× in Q1 2026.

What does price / book mean?

Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

JBIO JBIO Price / book

Price / book at other companies

Vertex PharmaceuticalsVRTX

5.9×-1.7×

Travere Therapeutics, Inc.TVTX

27.8×-20.7×

Vera TherapeuticsVERA

5.7×+2.9×

AnaptysBio, Inc.ANAB

125.1×+108×

Avalo TherapeuticsAVTX

5×+4.3×

Cullinan Therapeutics, Inc.CGEM

1.5×+0.3×

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B+318%

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

market cap/total stockholders equity=2.3×

Based on the most recent quarter.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's price / book?: JBIO (JBIO) reported price / book of 2.3× in Q1 2026.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.